What do systematic reviews say?

Direct antivirals (grazoprevir and elbasvir) vs placebo

The review found no eligible studies for this question.

• Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Pegylated interferon + ribavirin (24 weeks) + initial telepravir (12 weeks) vs pegylated interferon (48 weeks) + initial telepravir (12 weeks) + initial low dose ribavirin (12 + 36 weeks)

The review found no eligible studies for this question.

• Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Pegylated interferon + ribavirin (24 weeks) + initial telepravir (12 weeks) vs pegylated interferon (48 weeks) + initial telepravir (12 weeks) + initial low dose ribavirin (12 + 36 weeks)

The review found no eligible studies for this question.

• Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Pegylated interferon + ribavirin (24 weeks) + initial telepravir (12 weeks) vs pegylated interferon (48 weeks) + initial telepravir (12 weeks) + initial low dose ribavirin (12 + 36 weeks)

It is very uncertain whether pegylated interferon + ribavirin (24 weeks) + initial telepravir (12… changes sustained virological response compared with pegylated interferon (48 weeks) + initial telepravir (12 weeks) +… (very low certainty).

• Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
  RR 1.02 [0.67, 1.56]
  1 study · 35 participants
  Very low

Pegylated interferon + ribavirin (24 weeks) + initial telepravir (12 weeks) vs pegylated interferon (48 weeks) + initial telepravir (12 weeks) + initial low dose ribavirin (12 + 36 weeks)

It is very uncertain whether pegylated interferon + ribavirin (24 weeks) + initial telepravir (12… changes end‐of‐treatment response compared with pegylated interferon (48 weeks) + initial telepravir (12 weeks) +… (very low certainty).

• Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
  RR 1.02 [0.67, 1.56]
  1 study · 35 participants
  Very low

Pegylated interferon + ribavirin (24 weeks) + initial telepravir (12 weeks) vs pegylated interferon (48 weeks) + initial telepravir (12 weeks) + initial low dose ribavirin (12 + 36 weeks)

The review found no eligible studies for this question.

• Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Standard interferon vs placebo or control

Standard interferon showed no clear difference in treatment discontinuation compared with placebo or control (moderate certainty).

• Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
  RR 4.59 [0.49, 42.69]
  4 studies · 116 participants
  Moderate

Pegylated interferon + ribavirin (24 weeks) + initial telepravir (12 weeks) vs pegylated interferon (48 weeks) + initial telepravir (12 weeks) + initial low dose ribavirin (12 + 36 weeks)

The review found no eligible studies for this question.

• Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Standard interferon vs placebo or control

Standard interferon showed no clear difference in adverse events compared with placebo or control (moderate certainty).

• Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
  RR 3.56 [0.98, 13.01]
  5 studies · 143 participants
  Moderate

Pegylated (PEG) interferon alpha‐2a vs standard interferon

Pegylated interferon alpha‐2a showed no clear difference in death compared with standard interferon (low certainty).

• Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
  RR 0.33 [0.01, 7.81]
  1 study · 50 participants
  Low

Pegylated (PEG) interferon alpha‐2a vs standard interferon

Pegylated interferon alpha‐2a showed no clear difference in relapse(recurrence after stopping) compared with standard interferon (low certainty).

• Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
  RR 0.72 [0.41, 1.25]
  1 study · 38 participants
  Low

Pegylated (PEG) interferon alpha‐2a vs standard interferon

Pegylated interferon alpha‐2a may leads to higher end‐of‐treatment response compared with standard interferon (low certainty).

• Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
  RR 1.53 [1.09, 2.15]
  1 study · 50 participants
  Low

Organisational interventions vs usual care

Summary of findings table ‐ Organisational intervention probably leads to lower residents with at least one physical restraint compared with usual care (moderate certainty).

• Interventions for preventing and reducing the use of physical restraints for older people in all long‐term care settings 2023 · Cochrane Headline outcomes only
  RR 0.86 [0.76, 0.94]
  4 studies · 3849 participants
  Moderate

Summary of findings table ‐ Simple educational intervention vs usual care

• Interventions for preventing and reducing the use of physical restraints for older people in all long‐term care settings 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 241 participants
  Moderate

Summary of findings table ‐ Simple educational intervention vs usual care

• Interventions for preventing and reducing the use of physical restraints for older people in all long‐term care settings 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 813 participants
  Low

Summary of findings table ‐ Simple educational intervention vs usual care

• Interventions for preventing and reducing the use of physical restraints for older people in all long‐term care settings 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 463 participants
  Low

Summary of findings table ‐ Simple educational intervention vs usual care

• Interventions for preventing and reducing the use of physical restraints for older people in all long‐term care settings 2023 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 1202 participants
  Very low

Summary of findings table ‐ Providing information about the residents? fall risk vs usual care

• Interventions for preventing and reducing the use of physical restraints for older people in all long‐term care settings 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 98 participants
  Low

Summary of findings table ‐ Providing information about the residents? fall risk vs usual care

The review found no eligible studies for this question.

• Interventions for preventing and reducing the use of physical restraints for older people in all long‐term care settings 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Providing information about the residents? fall risk vs usual care

The review found no eligible studies for this question.

• Interventions for preventing and reducing the use of physical restraints for older people in all long‐term care settings 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found